During the last session, Bionano Genomics Inc (NASDAQ:BNGO)’s traded shares were 3.93 million, with the beta value of the company hitting 2.31. At the end of the trading day, the stock’s price was $0.21, reflecting an intraday loss of -6.77% or -$0.01. The 52-week high for the BNGO share is $2.27, that puts it down -980.95 from that peak though still a striking -4.76% loss since the share price plummeted to a 52-week low of $0.22. The company’s market capitalization is $21.36M, and the average intraday trading volume over the past 10 days was 3.91 million shares, and the average trade volume was 2.16 million shares over the past three months.

Bionano Genomics Inc (BNGO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. BNGO has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.14.

Bionano Genomics Inc (NASDAQ:BNGO) trade information

Bionano Genomics Inc (BNGO) registered a -6.77% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.77% in intraday trading to $0.21, hitting a weekly high. The stock’s 5-day price performance is -24.38%, and it has moved by -31.95% in 30 days. Based on these gigs, the overall price performance for the year is -85.66%. The short interest in Bionano Genomics Inc (NASDAQ:BNGO) is 9.83 million shares and it means that shorts have 3.81 day(s) to cover.

The consensus price target of analysts on Wall Street is $2, which implies an increase of 89.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $175 respectively. As a result, BNGO is trading at a discount of -83233.33% off the target high and -376.19% off the low.

Bionano Genomics Inc (BNGO) estimates and forecasts

Statistics show that Bionano Genomics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Bionano Genomics Inc (BNGO) shares have gone down -81.14% during the last six months, with a year-to-date growth rate more than the industry average at 60.75% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 85.42% this quarter and then jump 72.44% in the quarter after that. In the rating firms’ projections, revenue will decrease -19.97% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.3M as predicted by 3 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 8.15M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.72M and 8.77M respectively. In this case, analysts expect current quarter sales to shrink by -41.24% and then drop by -7.05% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 23.59%. While earnings are projected to return 77.19% in 2024.

BNGO Dividends

Bionano Genomics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Bionano Genomics Inc (NASDAQ:BNGO)’s Major holders

Bionano Genomics Inc insiders own 0.15% of total outstanding shares while institutional holders control 12.81%, with the float percentage being 12.83%.